New research presented at ADCES23 links engagement in Dario's
digital health solutions with improved outcomes
NEW
YORK, Aug. 24, 2023 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced new research presented at
the ADCES23 Annual Conference held earlier this month in
Houston, Texas. The new research
demonstrates Dario's ability to sustainably improve health outcomes
for users with diabetes over a two-year period.
Dario's digital health solutions combine a clinically
intelligent platform with billions of consumer insights to help
drive sustainable behavior change to improve the management of
chronic conditions and improve health outcomes. The latest research
analyzed the data of 119,482 Dario members to understand the
relationship between improving engagement and health outcomes.
The results showed that during the two years of data analyzed in
the research study, users improved engagement 29% over two years.
Users with high-risk diabetes demonstrated reductions in their
high-blood glucose reading ratios and monthly average glucose that
correlated with increased engagement.
"Dario's solutions are designed to engage members for the
purpose of driving healthier behaviors and outcomes. This new
research provides evidence that our approach to outcome-based
engagement provides a long-term benefit for our members and our
partners with sustainable health improvements," said Yifat
Hershcovitz, PhD, Vice President of Clinical and Scientific Affairs
at Dario.
"Every facet of our solution is designed with one goal in mind:
sustainably improving health outcomes. This new research, like many
of our studies, helps extend our understanding – and the market's
understanding – of what Dario digital health solutions are doing to
achieve that goal and deliver the results our partners have come to
expect," said Omar Manejwala, M.D.,
Chief Medical Officer of Dario.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the potential benefits realized by the use of its products, the
Company's belief that the improved clinical outcomes are
sustainable for two years and the Company's belief that its
approach provides a long-term benefit for its members and its
partners with sustainable health improvements. Without limiting the
generality of the foregoing, words such as "plan," "project,"
"potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
Media Contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
View original
content:https://www.prnewswire.com/news-releases/dario-publishes-new-research-demonstrating-greater-engagemenet-and-improved-clinical-outcomes-sustainable-for-two-years-301909091.html
SOURCE DarioHealth Corp.